Improvement of Walking Distance by Defibrotide in Patients with Intermittent Claudication

Summary Defibrotide is an antithrombotic drug which enhances prostacyclin production and activates fibrinolytic system. The aim of this study was to investigate the improvement of walking distance in patients with intermittent claudication treated with defibrotide. DICLIS was a double blind, placebo-controlled study which included patients with walking distance autonomy at a standardized treadmill test ≤350 ≥100 meters. A total of 310 patients were randomly allocated to placebo (n = 101), defibrotide 800 mg/day (n = 104) or defibrotide 1200 mg/day (n = 105). During a one year follow-up, the Absolute Walking Distance (AWD) was measured six times (0, 30, 60, 90, 180, 360 days). Similar improvement in walking distance was found in the three groups until the 90th day; thereafter placebo group showed no further increase, while AWD continued to increase in the defibrotide groups. Between the 180th and 360th day visits, AWD was significantly higher (P <0.01) in patients given defibrotide than in patients given placebo. No difference in efficacy was observed between the two dosages of defibrotide. No differences in side effects were observed among the three groups. The results of the present trial suggest that long-term administration of defibrotide improves walking distance in patients with intermittent claudication. Abbreviations: DICLIS = Defibrotide Intermittent CLaudication Italian Study, AWD = Absolute Walking Distance, IC = Intermittent Claudication, PVD = Peripheral Vascular Disease, LVOCF = Last Valid Observation Carried Forward, ITT = Intention-To-Treat Appendix, please see p. 676.

[1]  D. Neuberg,et al.  Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. , 1998, Blood.

[2]  Fowkes,et al.  Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants , 1998, British journal of haematology.

[3]  B. Everitt,et al.  Analysis of longitudinal data , 1998, British Journal of Psychiatry.

[4]  J. Bagger,et al.  Effect of verapamil in intermittent claudication A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. , 1997, Circulation.

[5]  D L Sackett,et al.  Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. , 1996, Circulation.

[6]  J. Manson,et al.  Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study , 1992, The Lancet.

[7]  R. Langer,et al.  Mortality over a period of 10 years in patients with peripheral arterial disease. , 1992, The New England journal of medicine.

[8]  J. D. Coffman.  Intermittent claudication--be conservative. , 1991, The New England journal of medicine.

[9]  C. Legnani,et al.  Modulation of arachidonate metabolite generation in human blood by oral defibrotide. , 1991, Arzneimittel-Forschung.

[10]  F. Violi,et al.  Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. , 1989, The Journal of laboratory and clinical medicine.

[11]  C. Alessandri,et al.  Inhibition of Tissue Plasminogen Activator Inhibitor by Defibrotide in Atherosclerotic Patients , 1989, Seminars in thrombosis and hemostasis.

[12]  A. Policicchio,et al.  Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. , 1988, Circulation.

[13]  J. Fleiss.  The design and analysis of clinical experiments , 1987 .

[14]  C. Wells,et al.  Coding ordinal independent variables in multiple regression analyses. , 1987, American journal of epidemiology.

[15]  G. Deichsel,et al.  DRUG-INDUCED INHIBITION OF PLATELET FUNCTION DELAYS PROGRESSION OF PERIPHERAL OCCLUSIVE ARTERIAL DISEASE A Prospective Double-Blind Arteriographically Controlled Trial , 1985, The Lancet.

[16]  G. Folco,et al.  Antithrombotic activity of a polydeoxyribonucleotidic substance extracted from mammalian organs: a possible link with prostacyclin. , 1981, Thrombosis research.

[17]  M. Arpaia,et al.  A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease. , 1991, Seminars in thrombosis and hemostasis.

[18]  C. Boselli,et al.  Effects of defibrotide on prostanoid synthesis and fibrinolytic activity in human veins , 1989 .

[19]  G. Rossoni,et al.  Beneficial effects of defibrotide against myocardial ischemia and decline of beta-adrenoceptor function in the rabbit. , 1986, Haemostasis.